Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near
normal life-expectancy. However, since the majority of patients will need to remain on …

INTRODUCTION Patients with chronic myeloid leukemia (CP-CML) failing 1 st line imatinib
are most commonly treated with the second-generation (2G) tyrosine kinase inhibitors (TKIs) …

Despite the success with tyrosine kinase inhibitors (TKIs) in most patients with chronic
myelogenous leukemia (CML), some patients still experience resistance or intolerance and …

Although imatinib remains the gold standard for first-line treatment of chronic myeloid
leukemia (CML), increasing recognition of imatinib resistance and intolerance has led to the …

We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-
TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to≥ 1 …

Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in
patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US …

Second-generation tyrosine kinase inhibitors (2GTKI) are more effective in inducing rapid
molecular responses than imatinib when used first-line in patients with chronic myeloid …

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

Introduction: In spite of the proven efficacy of the tyrosine kinase inhibitor (TKI), imatinib, in
chronic myeloid leukemia (CML), many patients develop intolerance and discontinue …